Prospective Multicenter Phase II Trial of 15-Minute Panitumumab Infusion with Irinotecan in Patients with Kras Wild-Type Chemo-Refractory Metastatic Colorectal Cancer: the Ship Trial

Trial Profile

Prospective Multicenter Phase II Trial of 15-Minute Panitumumab Infusion with Irinotecan in Patients with Kras Wild-Type Chemo-Refractory Metastatic Colorectal Cancer: the Ship Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Irinotecan (Primary) ; Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms SHIP
  • Most Recent Events

    • 21 Oct 2015 New trial record
    • 28 Jun 2014 Results presented at the 16th World Congress on Gastrointestinal Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top